Cabaletta Bio Inc. (CABA) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CABA scores 33 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillars are Whale 13F Flow and Insider Conviction, both of which sit at the low end of their ranges, while the Fundamental Cash Engine reflects a negative return on invested capital and zero free-cash-flow yield. The Forensic Balance Sheet score is the strongest of the five but still only half of its maximum. For a prospective investor, the rating implies that the reported cash-generation profile, institutional and insider signals, and balance-sheet quality all weigh against the position at current levels. The 52-week range of $1.32 to $4.23 against a price of $1.59 shows the stock trading near the lower end of its recent band, which an investor would need to weigh against the negative fundamental and flow readings rather than treat as a standalone signal.

Cabaletta Bio Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, the market capitalization is $0.3B. The source data does not identify the company's specific products, customers, or revenue model. Reported revenue for FY 2025 is $0.0M, consistent with the absence of revenue in the reported periods.

Per the SEC financials, reported operating and net losses widened across the three periods, with operating income moving from $-74.7M in FY 2023 to $-172.2M in FY 2025. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 of 9, per the forensic balance-sheet inputs in the Roarable RQD rating. Cash declined from $164.0M in FY 2024 to $83.0M in FY 2025, and Debt/Equity is 0.5; period-level debt values are not available in source data.

Per the news wire, six items reference CABA. Two are flagged RISK WATCH (RED): a Timothy Sykes report headlined "CABA Stock Slips As Traders Weigh Cash Runway And Losses," and a StocksToTrade report with a similar cash-runway theme. Four are flagged YELLOW as MARKET WIRE: a Seeking Alpha item on a 40% sell-off and cash concerns, a TradingView estimates page, a Simply Wall St item on insider purchases losing roughly US$60k, and a MyChesCo item on 385,000 stock options granted to new hires. The news wire lists no proprietary signals in the Butterfly graph. The recurring catalyst themes across the wire are cash runway, losses, and the sell-off, with insider and option-grant activity as secondary items.

Per the Butterfly Supply-Chain Graph, supply chain: NONE; butterfly links: none; proprietary signals: none. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The sector classification (Health Care / Biological Products) and beta of 1.0 are the only available context for sensitivity to broader biotech moves, and the source data does not quantify any such correlation.

• What is the company's product pipeline, and what clinical or regulatory milestones are scheduled, given the absence of revenue in reported periods?
• What is the explanation for the cash decline from $164.0M to $83.0M, and what is the runway implied by the FY 2025 burn rate of $-132.3M in FCF?
• What are the period-level debt figures behind the Debt/Equity of 0.5, given that debt is listed as N/A in every reported period?
• What is the scope and timing of the insider purchases and the 385,000-option grant referenced in the news wire?
• What is the supply-chain and partnership exposure, given that the Butterfly graph reports no links?